RAPT Therapeutics, Inc.

NasdaqGM:RAPT 주식 리포트

시가총액: US$1.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

RAPT Therapeutics 경영진

경영진 기준 점검 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

최고경영자

n/a

총 보수

CEO 급여 비율n/a
CEO 재임 기간no data
CEO 지분 보유율n/a
경영진 평균 재임 기간3.2yrs
이사회 평균 재임 기간1.2yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • Jan 20

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

Summary RAPT Therapeutics, Inc. is being acquired by GSK plc, aka GlaxoSmithKline, for $2.2 billion, driven by its promising anti-IgE antibody ozureprubart. Ozureprubart offers a potential best-in-class profile with extended half-life, enabling dosing every 8–12 weeks versus XOLAIR’s 2–4 weeks. The Phase 2b prestIgE trial is underway for IgE-mediated food allergy, leveraging strong proof-of-concept data in chronic spontaneous urticaria. I maintain a Buy rating on RAPT, citing pipeline progress, the acquisition that happened, and the broad applicability of ozureprubart to IgE-mediated disorders. Read the full article on Seeking Alpha
분석 기사 • Jul 16

We're Keeping An Eye On RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Mar 28

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 16

Still Cautious Over RAPT Therapeutics' Fresh Start With RPT904

Summary RAPT Therapeutics pivoted from a failed inflammation asset (RPT193) to focus on RPT904 for food allergies. RPT904, an IgE-inhibiting mAb licensed from Jemincare, is in Phase 2 for food allergy, CSU, and asthma. The licensing deal includes a $35 million upfront fee plus milestones and royalties, with rights outside China, Hong Kong, and Macau. This gives RAPT a new “fresh start” with roughly $241.4 million in resources to fund its latest bet on RPT904 targeting FA. However, I’m still neutral on RAPT, as the recently issued shares could be a headwind. Also, the company’s bet on RPT904 remains speculative until Jemincare reports its Phase 2 data. Read the full article on Seeking Alpha
분석 기사 • Nov 10

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 24

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Summary Data from phase 2b study, using zelnecirnon for the treatment of patients with atopic dermatitis, is expected in Q3 of 2024; Potential for FDA clinical hold to be removed. The global atopic dermatitis market is expected to reach a valuation of $19.49 billion by the end of 2034. Preliminary ORR data established shows that tivumecirnon might ultimately be effective in treating CPI-naive NSCLC and CPI-experienced advanced HNSCC patients. The company had $141.6 million in cash as of March 31st of 2024; enough to fund its operations for at least the next 12 months. Read the full article on Seeking Alpha
분석 기사 • Jun 13

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • May 20

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Summary RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Liver failure in a single patient with a complex medical history resulted in a clinical hold by the FDA, leaving RAPT no choice but to unblind both ongoing ph2 studies. The probability that zelnecirnon caused the hepatic failure is low considering alternative explanations and no prior preclinical/clinical evidence of liver toxicity. If ph1b results are replicated, I expect the ph2 readout to be positive with available patients, despite premature halting of the trial. Subsequently, I expect the lifting of the FDA clinical hold. Read the full article on Seeking Alpha
분석 기사 • Feb 21

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Sep 12

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • May 10

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Feb 07

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
분석 기사 • Oct 12

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Jan 25

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Oct 15

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Jun 08

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
분석 기사 • Mar 15

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

CEO

RAPT Therapeutics에는 CEO가 없거나 해당 데이터가 없습니다.

리더십 팀

이름직위재임 기간보수지분
William Ho
Strategic Consultant10.8yrsUS$2.31m0.0079%
$ 141.4k
Justin Huang
Presidentno data데이터 없음데이터 없음
Steve Young
Vice President of Technologyno data데이터 없음데이터 없음
Dirk Brockstedt
Chief Scientific Officer6.8yrsUS$1.48m데이터 없음
Michael Listgarten
General Counsel3.2yrs데이터 없음데이터 없음
Paul Kassner
Senior Vice President of Biology6yrs데이터 없음데이터 없음
Jennifer Nicholson
Senior Vice President of Regulatory Affairs & Quality Assurance3.5yrs데이터 없음데이터 없음
Nipun Davar
Senior Vice President of Technical Operations2.1yrs데이터 없음데이터 없음
Lisa Moore
Senior Vice President of Business Development & Strategy1.1yrs데이터 없음데이터 없음
Kevin Ryan
VP, Treasurer & Directorno data데이터 없음데이터 없음
3.2yrs
평균 재임 기간
57.5yo
평균 나이

경험이 풍부한 관리: RAPT의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.2 년).

이사회 구성원

이름직위재임 기간보수지분
Justin Huang
Presidentno data데이터 없음데이터 없음
Kevin Ryan
VP, Treasurer & Directorno data데이터 없음데이터 없음
Hugh Sampson
Member of Scientific Advisory Board1.2yrs데이터 없음데이터 없음
Alexander Rudensky
Chairman of Scientific Advisory Boardno data데이터 없음데이터 없음
Emma Guttman-Yassky
Member of Scientific Advisory Board6.7yrs데이터 없음데이터 없음
Robert Zamboni
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Lisa Beck
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Sharon Chinthrajah
Member of Scientific Advisory Board1.2yrs데이터 없음데이터 없음
1.2yrs
평균 재임 기간

경험이 풍부한 이사회: RAPT의 이사회는 경험이 부족한 것으로 간주됩니다(평균 재임 1.2 년) — 신규 이사회일 가능성이 있습니다.

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/03/05 15:35
종가2026/03/02 00:00
수익2025/09/30
연간 수익2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

RAPT Therapeutics, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Gao Yi ChenBerenberg
Guyn KimBMO Capital Markets Equity Research
Zegbeh JallahCapital One Securities, Inc.